Task B26: Drug Synthesis Activities for SARS-CoV-2

NIH Pandemic-Era Grants

Pandemic Era Grants

2022

↗ Live URL (may be dead)

Document text

Principal Investigator: BRUCE  BLOUGH
Organization: RESEARCH TRIANGLE INSTITUTE
Fiscal Year: 2022
Award: $97,008
Funding agency: National Institute of Allergy and Infectious Diseases

This task provides for lead identification, development, chemistry and synthesis services under the NIAID Preclinical Services for the Development of Interventional Agents Program.

Terms: <2019 novel corona virus><2019 novel coronavirus><2019-nCoV><COVID-19 therapeutics><COVID-19 virus><COVID19 therapeutics><COVID19 virus><Chemistry><CoV-2><CoV2><Development><Drug Synthesis and Chemistry><Interventional Agent Development><Lead><NIAID><National Institute of Allergy and Infectious Disease><Pb element><SARS corona virus 2><SARS-CO-V2><SARS-COVID-2><SARS-CoV-2><SARS-CoV-2 therapeutics><SARS-CoV2><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-coronavirus-2 therapeutics><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><Services><Severe Acute Respiratory Coronavirus 2><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome coronavirus 2 therapeutics><Severe acute respiratory syndrome related corona virus 2><Wuhan coronavirus><coronavirus disease 2019 therapeutics><coronavirus disease 2019 virus><coronavirus disease-19 virus><developmental><drug synthesis><hCoV19><heavy metal Pb><heavy metal lead><nCoV2><pre-clinical><preclinical><programs><therapeutic agent development><therapeutic development><therapeutics against COVID-19><therapeutics against COVID19><therapeutics against SARS-CoV-2><therapeutics against SARS-coronavirus-2><therapeutics against Severe acute respiratory syndrome coronavirus 2><therapeutics against coronavirus disease 2019><therapeutics for novel coronavirus>